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PATIENTS with leukemia, metastatic carcinoma and sarcoma possess altered
carbohydrate metabolism as shown by reduced glucose tolerance (Marks and
Bishop, 1957), and elevated resting venous lactic acid (Cori and Cori, 1925).
Enzymes concerned in tissue glycolysis are often increased in activity in serum
during neoplastic disease progression, including phosphohexose isomerase
(Bodansky, 1954b), aldolase (Sibley Fleischer and Higgins, 1955), and lactic
dehydrogenase (Hill and Levi, 1954). Acid phosphomonoesterases hydrolyzing
three-carbon substrates produced during glycolysis are also increased in activity
in venous blood from patients with breast and prostate cancer (Reynolds, Lemon
and Byrnes, 1956). Observations indicating possible abnormalities of the Krebs
tricarboxylic acidcycle in human cancerpatients however are limited to increased
DPN-dependent dehydrogenase activity in sera of patients with hepatic meta-
stases (Wolfson, Spencer, Sterkel, and Williams-Ashman, 1958 ; Schwartz,
Greenberg, and Bodansky, 1959), and a single report of abnormal venous citric
acid (Kyle and Canary, 1957). In this communication we are reporting hyper-
citricemia as a frequent abnormality of untreated advanced cancer. A
preliminary account of these observations has been published elsewhere (Lemon,
Mueller, Looney, Chasen and Kelman, 1959).
METHODS
Citrate concentration in blood obtained from various sites has been determined
utilizing the Ettinger modification of the highly specific pentobromoacetone
method (Ettinger, Goldbaum and Smith, 1952). Blood samples were obtained
from volunteers and patients following a 12-hour fast and analyses performed in
duplicate in most instances. Chloral hydrate which is the only known drug
possibly reacting to this proceedure has not been administered within 12 hours
to most of the patients or any of the volunteers studied. As a further check on
the methods used, citric and other organic acids have been separated and
concentrated from seraby a methoddevelopedby Dr. H. H.Wotiz, using 4N KOH
to precipitate serum proteins followed by neutralization to pH 6-0 with co'ncen-
trated HCI. The precipitate was centrifuged and washed once with distilled
H20. The washings combined with the supernate were made slightly alkaline
* Present address: Massachusetts Memorial Hospitals, 750 Harrison Avenue, Boston 18,
Massachusetts.
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with 2-5 N NaOH, and reacidified by bubbling C02 through the solution. These
extracts were evaporated to dryness, resuspended in 1.0 c.c. ethanol and then
chromatographed, along with reference citrate standards (Stark, Goodbar, and
Owens, 1951). The citrate zone was then eluted, and the Ettinger procedure
applied to the extract. A close agreement with the original analysis of unex-
tracted serum was usually obtained in sera from cancerous and non-cancerous
patients, indicating that citrate rather than some other organic acid was actually
being measured.*
Blood was obtained in some volunteers and patients by simultaneous posterior
iliac crest aspiration, arterial puncture and venipuncture. Following the initial
sample 0-5 g. of sodium citrate as a 4 per cent solution was injected intravenously
in a two minute period in manypatients, with additional venous samples obtained
at .5, 101 20 and 30 minutes following commencement of injection. Since it was
soon found that citrate concentration decreased rapidly with time between
5-30 minutes afterinjection, comparable to a first order reaction (Lemon, Mueller,
Looney, Chasen and Kelman, 1959), only 5 and 30 minute samples were routinely
collected for measurement of clearance rates. Analysis of serum calcium (Clark
and Collip, 1925), phosphorus (Fiske and Subbarow, 1925) and glucose before
and 30 minutes following injection was performed on a sample of 40 patients.
Periodic serum calcium, phosphorus and alkaline phosphatase (Bodansky, 1932)
analyses were performed in addition on most of the cancer patients.
Simultaneous observations ofcopper-resistant serum acidphosphatase, (Reynolds,
Lemon and Byrnes, 1956) and glutamic oxalacetic transaminase, (Franco, 1957)
were made on the same serum sample, in a representative series comprising many
of the cancer patients.
Patients were classified according to the nature of their principal disease.
Biopsy proof of cancer was obtained in all the cancer patients investigated, and
the extent and location of their metastases was assessed from clinical and radio-
logic diagnostic procedures. Table I summarizes the diagnostic information on
the patier-ts studied.
In the statistical evaluation of data, only the initial serum-observation was
utilized for the comparison of means between different groups of patients with
various diseases. This tends to underestimate the frequency of elevated blood
citric acid, which is more frequent in the more advanced stages of cancer, but is
iiecessary for a true comparison between cancer and other diseases, in which only
a single observation was available for each case. Hypercitricemia has been
defined as serum citrate value exceeding twice the standard deviation ofthe mean
of healthy volunteers of the same sex, a value which is at the 95 per cent level
of confidence for abnormality.
RESULTS
1. Citrate dynamics
The increase of serum citrate from 0-5 minutes A) was regarded as the
result of rapid dilution of the 0-5 g. dose into plasma and extracellular fluid, an
* The analytic procedure has repeatedly yielded 95-98 per cent recovery of citrate added to
whole blood or serum. Excellent checks within 2-3 per cent accuracy have been obtained when
duplicate analyses for citrate were carried out using the method reported by Saffron and Dendstadt
(1948). All sera were immediatley frozen upon separation from clot and analyses should be carried
out within a few days of collection. Frozen sera may show 5-10 per cent changes in citrate con- centration with prolonged storage. Simultaneous citrate standards were routinely run with each
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TABLEI.-Cla8sification of Clinical Material
Number
of
Diagnosis Source of material patients Nutrition Stage of Disease
Healtby volunteers Medical students. Hos- 71 Excellent
pital personnel
Rheumatoid and de- Ambulatoryout-patients, 32 Good Stage 11. 111. American
generative arthritis with 15-year docu-- Rheumatism Associa-
irnented history tion.
Non-cancer disorders Chiefly hospital patients, 33 Good to fair
some bed-fast
Pre-malignant lesions Ambulatory out-patients 28 Excellent to
and benign tumours andhospitalin-patients good
Carcinoina and sar- Ambulatory and bed-fast 195 Good to fair All stages, froni early
coma hospital patients localized surgically
cured to distant me-
tastases.
Total 358
assumptioii which appears valid (Bunker, Stetson, Coe, Grillo, andMurphy, 1955).
This distribution space S was determined by dividing the total in Itg. (0-5 x 106)
by A given in jig. per ml. In healthy volunteers and cancer patients the mean
for this space was 21-6 liters for males and 14-0 liters for females (Table 11).
Following the peak concentration of citrate 5 minutes after start of injection
serum citrate concentration rapidly declined in a semilogarithmic manner
compatible with a first order reaction, the initial baseline concentration very
nearly being attained in normal, arthritic and cancer patients at 30 minutes time
(Lemon, Mueller, Looney, Chasen and Kelman, 1959). The rate of decrease of
serum citrate concentration approximated I jig./ml./min., which when multiplied
by 8 x 60 in each case provided an estimate ofthe hourly rate of citrate clearance
fromplasma and extracellular fluid, by diffusion, metabolism, and renal excretion.
In normal males, plasma clearance approximated 900 mg. per hour and in females,
800 mg. per hour. Urinary citrate excretion was not measured, since preliminary
studies showed poor correlation between serum and urine citrate concentration.
Citrate excretion in the urine appears to fluctuate quite independently of serum
values owing to high renal uptake and metabolism (Herndon and Freeman, 1958).
Only a small fraction of plasma citrate passing through the kidney is excreted,
the amount being affected by acid-base balance and vitamin D content of the
diet (Yarbo, 1956).
2. Fa-sting venoU8citrate concentration-s and di8ea8e
In conformity with observations published by Rechenberger and Benndorf
while this study was underway (Rechenberger and Benndorf, 1956), the mean
venous citrate concentration ofhealthy females was found to exceed that of males
of comparable age groups (Fig. 1 ; Tables 11, 111). The mean fasting venous
concentration of male and female patients with rheumatoid and osteoarthritis
was almost identical to that of their sex-matched volunteer controls.
Patients with benign tumours such as benign prostatic hyperplasia and mam-
mary dysplasia had citrate concentrations also within the normal range for their379 HYPERCITRICEMIA IN HUMAN CANCER
TABLE II.-Observatiom of Citrate Dynamic-3 in Healthy Volunteers and
Patients with Benign Diseases
Mean
fasting
venous
Number citrate
of concen-
Sex cases tration
Frequency
of
observation
above
Range 2 x S.D.
Distribution
space
(liters
±S.E.)
Clearance
rate
(mg./hr.
±S.E.)
896±58
799±38
Group
Normal
Voluiiteers I 21-6±2- 4 .
(p=0-012)*
2 . 14-9±1- 3 .
. M.
F.
. 27
. 44
71
. I"27-2± 1-3 . 16-4- .
(p<0.001)* 45.7
. 38-3± 1-8 .
3=4-2%
Non-cancer
Hepatic cirrhosis
Osteo-porosis
.
Pregnancy
Other disease
M. . 3
F. 4
519 2
9 . 3
M. 10
F. 10
M. 23
91 9 9
. 33- 9
. 46- 5
. 25- 0
. 34-5±5- 7
. 39- 1±4- 8
. 27
-9±1- 2
. 26-5±0- 4
18-
61- 1
34- 8- .
51.0
20- 2- .
38- 4
14- 4- .
31- 0
14- 8- .
84- 9
20- 4- .
64- 4
. 20-39 .
23- 5- .
30- 5
0
0
0
I
1
0 . 31-4±4- 8 .
0 . 26-5±2- 1.
I 1027±33
955±71
Rheumatoid arthritis
Osteo- and degenera-
tive arthritis
65 3=4-6%
Pre-nmlignant
Mammarydysplasia
- F.
M.
13
2
12
27
. 163
. 30-4±2-7
. 16-1- .
49-9
24-0- .
58-5
.29-0±2-6 . 15-7- .
44-8
0
1
2
Gynecomastia
.
Benign prostatic hy- ,
perplasia
Grand total . - -
3=11-1%
. .. . 9=5.5%
.
Significance between upper and lower figures.
sex. However, a few patients with carcinomas amenable to surgical excision
and with clinically detectable metastases showed abnormal elevation of fasting
venous citrate concentrations (Table 111).
Women of all age groups with untreated metastatic carcinoma of the breast,
had fasting venous citrate concentrations significantly (p
= < -01) in excess of
volunteers, arthritic females or women with mammary dysplasia (Tables II, IV).
Concentrations of venous citrate often exceeded more than 57 jig./ml. in untreated
patients with advanced disease orpatients in terminalrelapsefollowing a hormone-
induced disease remission. Equally high citrate concentrations were noted in
male patients with a variety of other types of metastatic carcinoma, including
bronchogenic andpulmonary carcinoma, gastrointestinal cai-cinoma, fibrosarcoma,
and lymphoma (Table III). Hypercitricemia of this degree has been noted only380 LEMON, MUELLER, LOONEY, CHASEN AND KELMAN
rarely in non-cancer patients, including one obese female with mild uncontrolled
diabetes melhtus, an anxious male with questionable peptic ulcer symptoms and
negative X-ray findings, and one case ofosteogenesis imperfecta.
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FiG. I.-Mean fasting serum citric acid concentration in healthy volunteer controls and
untreated metastatic breast cancer in females, grouped by age decade. Small numbers at
each point indicate number ofpatients observed. Horizontal dashed line indicates mean,
with range of standard error indicated by upright bracket at left, for the entire series of
patients in each of the three classifications.
0 Untreated metastatic breast cancer (24).
Contro18
0 0 Female (55).
r-i r-1 male (37).
The discrepancy between the total cases and the sums at each point in this chart
represents those rare cases for whom age was unknown from available records and
solitary cases of other age decade categories which were not suitable for plotting as
meam.
3. Citrate clearame rate and disease
No significant sex difference was noted in mean citrate clearances (Table II).
Male patients with extensive rheumatoid arthritis cleared injected citrate from
their blood stream at rates which did not differ significantly from male or female
normal volunteers. There was no significant deviation from volunteers in the
average rate ofcitrate clearancebypatients withvarious cancers otherthanbreast,
except for males with inactive post-therapy non-breast cancer, who showed a
subnormal mean clearance rate in the small group tested (Table III). However,
untreated patients with dimeminated breast cancer tended to have the highest
mean rate of citrate clearance, ofany ofthe groups studied, as well as the highestHYPERCITRICEMIA IN HUMAN CANCER
TABLE III.-Observation8 of Citrate Dynamics in Patients with Cancer
Mean fasting
venous
citrate Frequency
(pg/ml. of observa- Distribution Clearance
Number + S.E. tions Number space rate
of initial exceeding of (liters (mg./hr.
Group Sex patients observation) Range 2 x S.D. patients + S.E.) + S.E.)
Non-breawt Cancer
Local, pre-operative . M. 5 36-3±5-6 15-7-50 3 .. .
F. 1 .. 72-5 1
Inactive post-therapy M. 7 36-0±4-3 16-9-52-9 2 8 18-7±3-6 490±107
F. 9 38-8±7-2 16-9-76-1 3 6 19-4±4-1 1013± 90
Active distant meta- M. 42 42-0±3-2 15-5-100 14 12 15-8±2-1 828±127
stases F. 35 35-7±2-2 12-1-69-9 3 8 18-2±2-6 715±130
Carcinoma of prostate M. 8 37-6±5-9 14-9-66-5 3
107 29=27%
Carcinona of Breast
Local,pre-operative . F. 6 27-8±2-7 20-7-39-5 0 .. .. ..
Inactive, post-therapy ,, 20 36-5±1-7 22-3-51-4 0 .. .
Active distant meta- ,, 41 52-1±3-5 19-4-116-6 11 18 18-2±2-7 992 ±72
stases no therapy
Active metastases ,, 3 . 22-9-72-6 1 .. .. (p<001)*
treated by sex hor-
mones
Active metastases ,, 18 46-2±5-6 19-4-93-0 4 26 15-5±1-5 720+ 59
treated by cortisone
or prednisone
88 16=18-4%
Grand total . 195 45=23% 78
* Significance of difference between upper and lowerfigures.
mean fasting venous citrate. Following therapy with adrenal corticoid hormones,
breast cancer patients showed a reduction of citrate clearance rates, as well as a
reduction in fasting citrate level.
In one patient with breast cancer, citrate clearance was simultaneously
measured in mixed venous blood, and in venous blood passingthrough the primary
tumour. The citrate clearance rate was identical in both areas, according to our
method of calculation (Table IV). This suggests that the difference in blood
citrate concentration in the two sites was not due to uptake of citrate by the
neoplasm.
These results would suggest increased citrate diffusion from some body tissue
accounting for the increased blood level, rather than reduced tissue utilization in
carcinomatosis. Bone which contains over 1 per cent citrate (dry weight), in
its organic matrix (Dickens, 1941 ; Thunberg, 1953) is one of the more obvious
sources for citrate release, but metastatic cancer and malignant tumour cells
themselves contain considerable amounts of citrate (Potter and Busch, 1950;
Dietrich and Shapiro, 1956; Miller and Carruthers, 1950).
4. Citrate distribution space and disease
A sex difference was noted in the mean distribution space ofhealthy volunteers,
which was statistically significant at a level of confidence (p = ± -012; Table II).
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TABLEIV.-Acid Phos hatase Activity and Citrate Concentration in Venous Blood
Draining Breast Cancer Primary Site, Compared to Mixed Venous Blood
Mixed venous blood from
right antecubital vein
r -.'% Acid
Citrate phosphatase
([Lg./ml.) (.Lmole/100 MI.)
26- 9 13-6
70- 0 30-2
Venous'blood from left
breast primary tumor
t
A
Acid
Citrate phosphatase
(.tg./ml.) (limole/100 ml.)
15 27-6
23-5 39-1
25- 8
Date Time
1/13/58 Fasting
5 minutes after
citrate injection
30 minutes after
citrate injection
1/16/59 Fasting
7 minutes after
injection
I0 minutes after
injection
26 minutes after
injection
29 minutes after
injection
Mean values
34- 5
33- 0
65- 5
16-4
25- 6
18- 8
29- 4 116- 5
33
- 5 27
- 2
35- 5 24- 5
19.5 28- 3
21- 6 29- 6 44- 2 21- 5
II
- 6 liters Citrate dynamics
1/13/58
Distribution
space
Clearance
rate
Distribution
space
Clearance
rate
990 mg./hr.
13
- 7 liters
1300 mg./hr.
29
- 4 liters
1300 mg./hr.
1/16/58
A sex difference was not seen however in either of two groups ofnon-breast cancer
patients, in whom the average male distribution space approached the female
value. Male rheumatoid arthritic patients, on the other hand possessed a higher
mean distribution space for citrate than healthy volunteers, and weresignificantly
different in this respect from all groups of male or female patients with active
metastatic cancer of breast as well as other types of cancer (p < -012). These
results suggest that the tissues of patients with rheumatoid arthritis are more
widely and rapidly permeable to injected citrate resulting in a 5 minute post-
injection peak value which is considerably smaller than observed in patients with
cancer, or healthy volunteers, as a result of dilution. This observation may be
related to the unusual property of citric acid in solubilizingpro-collagen (Jackson,
1957).
5. Variations in citrate concentration in blood obtainedfrom various sites
Citric acid obviously is in a state ofrapid flux in the blood, with removal rates
in the vicinity of 0-8-0-9 g./hr. which must be matched by release of citrate into
blood at anequivalent rate. In an effort to learn more about thisphase of citrate
metabolism, venous samples were obtained from blood leaving a large mucoid
adenocarcinoma of the breast, and compared to mixed venous blood from an
antecubital vein::383 HYPERCITRICEMIA IN HUMAN CANCER
ABSTRACT
Case No. 1. This Patent, F. W., aged 65, Boston City Hospital No.
1630205, had a I I x 15 x 15 cm. untreated neoplasm of the left breast
reported as mucin secreting adenocarcinoma by biopsy. Two large
superficial veins were noted draining the massive primary lesion, passing
from the mid left thorax upward to anastomose with communicatilig
branches to the left internal mammary vein. Two citrate tolerance tests
were carried out, 1/13/58 and 1/16/58, before and after 30 mg. daily of
prednisone therapy, starting 1/14/58 (Table IV). A radical mastectomy
on the left was performed on 1/20/58, with 8 negative lymph nodes found.
A right radical mastectomy was performed on 1/31/58 for a simultaneous
primary oii the other side, measuring 1-0 x 1-4 x 1-0 cm., reported as
medullary and scirrhus carcinoma, also with negative lymph nodes.
The results demonstrated clearly a decreased citrate concentration in blood
leaving thisparticular cancer, although acidphosphataseactivity, which is believed
to diffuse from maligiiant tumours, (Lemon, Davison, and Asimov, 19054), was
definitely increased. The latter observation confirms that we were examiniiio, a
bloodsample in the tumour venous bed which differedsignificantly in its properties
from mixed antecubital venous blood, in all six samples. As a result of this
observation, some other major source than tumour tissue for citrate diffusion
into blood had to be postulated to explain the elevated serum citrate noted in
breast and other cancer patients. Simultaneous blood samples from iliac bone
marrow, brachial or radial artery, and antecubital vein were then obtained, in a
series ofhealthy volunteers, and cancer patients. A uniform decreasing gradient
of citrate concentration from marrow to artery to vein was observed both in
representative normal individuals and in cancer patients (Table V).
TABLEV.-Relative Concentration o Citric Acid in Bloodfrom VarioU8 Site-8
Meaii eitrate coi-icentration
Arterial blood Venous blood
(as % of (as % of
Alarrow blood marrow i-i-iarrow
Group No. Sex (Pg-1ml-) concentration) conceiitration)
Healthy volunteers I I TNI. 34- 1 89 73
(4 cases)
(range 81-94) (range 51-92)
Metastatic cancer patients 8 F. 45 0 93 86
(6 under treatment) (range 87-98) (range 67-95)
6. Serum calcium andpho8phorus concentration
The ii-ijection of 0-5 g. of sodium citrate did not significai-itly change serum
calcium, phosphorus or glucose concentration in a sample of 40 patients within
the 30 minute period of observation. Hypercaleemia above 12-0 mg. per cent
was noted in only one out of 45 patients with active metastatic breast cancer in
this study, and in only two out of 85 patients with other types of metastatic
cancer. One of the latter cases was a functioning parathyroid carcinoma. The
mean serum calcium and phosphorus concentrations for patients sampled withiii384 LEMON, MUELLER, LOONEY, CHASEN AND KELMAN
TABLEVI.-Calcium Phosphorus and Blood Sugar Observatiom
Fasting
Number Venous Venous venous
of calcium phosphate blood sugar
Group Sex cases (mg./100 C.C.) (mg./100 C.C.) (mg.1100 C.C.)
Healthy volunteers M. 15 10- 2+ O- 27 2- 8+0- 08 87
- 8+0
- 33
F. 20 10- 1±0- 03 3-2±0-19 97 ±4
- 5
(4 cases)
Rheumatoid arthritis M. 23 10- 1±0-15 3- 1±0- 12 91-8±4- 0
Osteo-arthritis . 9 9 9-7±0- 31 2
- 7+0- 15 88- 1±2- 8
Metastatic carcinoma, breast F. 23 10-2±0- 48 4-2±0
No therapy
Same, during prednisone
therapy :
Less than 6 months 10 10-1±0- 52 3- 6±0- 28
More than 6 months 8 10-0±0- 24 3-5±0- 21
Other metastatic carcinoma M. 17 10-4±0- 45 3
-8±0- 08
No therapy
Other metastatic carcinoma F. 9 9
-9±0- 37 3
-6±0- 04 87
-0±8
- 4
No therapy
the various groups is shown in Table VI. After an initial group of cancerpatients
had been sampled, serum calcium concentration was not ascertained except in
those who by virtue of extent of metastases or clinical symptoms were considered
likely subjects for hyperealcemia. In all these cases, no relationship was ascer-
tainable between the level of serum calcium, and citric acid (Fig. 2). In a patient
with a functional metastatic carcinoma of the parathyroid gland, elevated citric
acid accompanied hypercaleemia only intermittently.
Metastases of other carcinomas than breast, and sarcomas in both sexes,
although sometimes associated with hypercitricemia also failed to show any
correlation with serum calcium or phosphorus concentration (Fig. 2).
7. Hypercitricemia and8ite of meta8tase8
The major sites of metastases were compiled in patients showing hypercitri-
cemia, which in some patients constituted at least two major areas (Table VII).
Not only was hypercitricemia noted in the absence of clinically demonstrable
metastasis, but it was noted in association with each of the maj'or areas of
metastasis. Extensive osteolytic activity was present in several patients with
metastatic breast cancer, or multiple myeloma without hypercitricemia. How-
ever, these patients were receiving some type of antitumour therapy at the time
of observation. Major hepatic involvement, which might affect citrate
metabolism, was present in only one-fourth of patients with hypercitricemia;
and adrenal metastases were uncommon. All the major pathologic types of
cancer thus far investigated may induce hypercitricemia sooner or later.
8. Hypercitricemia and cancer therapy
In our preliminary report it was emphasized that hypercitricemia was encoun-
tered far more often in patients whose cancers had not received any recent anti-
tumour therapy (Lemon, Mueller, Looney, Chasen and Kelman, 1959). A more
extensive analysis by cases indicates a substantially similar picture, with the
highest frequency (55 per cent) of abnormal citrate values in patients prior to any385 HYPERCITRICEMIA IN HUMAN CANCER
form ofanti-cancer treatment (TableVIII). Thetype oftherapy utilizeddiffered,
in that while most of the breast cases were receiving prednisone, patients with
cancer arising from other sites were receiving radiation or analgesic drug therapy
only. In several patients, serial observations showed a steady rise in venous
citrate concentration in their terminal stages of cancer, in spite oftherapy which
was obviously ineffective.
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9. Hypercitricemia and -serum enzymatic hyperactivity
The battery of serum enzyme analysis was not extended to the arthritics or
healthy volunteers included in this project since ample data was available in the
'literature concerning the
" normal
" values for these disease parameters, and also
from our own studies of other groups of patients (Reynolds, Lemon and Byrnes,
1956). Copper-resistant acid phosphatase was elevated above normal in venous
blood in the majority of the untreated breast cancer patients, and tended to--"N
Anti-cancer therapy
concurrently or within
past 6 months
-A
I
Total cases Elevated (*)
f-
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TABLEVII.-Location ofPrincipal Meta8ta8e,8in Patient8withHypercitricemia
Location of'metastases
A 't r
Local Lung,
recurrence pleura, Liver,
and/or media- portal
lymphatic stinium area Bone Remarks
Pathological
diagnosis
ofneoplasm
A. Sarcoma
B. Epidermoid and un-
differentiated car-
cinoma
C. Adenocarcinoma
(non-breast)
D. Adenocarcinoma of
breast
E. 0ther
Total patients with hy-
percitricemia (initial
observations)
Number
of
patients
3 1 2 1 Adrenals (1).
13 4 4 2 2 Adrenals (1).
8 5 3 3 1 Brain (1).
16 3 5 5 Brain (2).
5 No metastases in car-
cinoma of bladder
(1), adenocareinoma
of colon (2), renal
cell carcinoma (1),
basal cell (1).
45 10 12 10 9 (No metastases pre-
(22%) (27%) (22%) (20%) sent in 10%).
TABLE VIII.-RelationofAnti-cancer Therapy to Occurrence,of Venous
Hypercitricemia in 101 Patients with Various Types of Cancer
Frequency ofhypercitricemia*
A
No anti-cancer therapy
during observation
t A._11
Total cases Elevated (*)
18 9
4 3
8 7
6 2
5 2
Source of cancer
Breast .
Other genito-urinary
Respiratory
Gastro-intestinal
Mesenchymal
.
Totals .
28
13
11
3
5
60
11
5
4
2
1
23
(38%)
41 23
(55%)
* > 2 x S.D. of normal mean venous citrate level (95 per cent level ofconfde,lce).
increase with time' especially during the second six months ofprednisonetherapy
(Table IX). Phosphohexose isomerase analyses showed a similar trend. The
data are insufficient to draw conclusions from either alkaline phosphatase or
transaminase measurements. Citrate concentration, however, decreased during
the first six months of prednisone treatment of breast cancer, to values well
within the normal range, before a latersecondary rise, suggesting different factors
influenced venous concentration of the latter during treatment compared to
variousenzymaticfunctions. Othertypes ofmetastatic cancer in men and women
also often had abnormal acid phosphatase and phosphohexose iseromase activity
as shown by the mean values, although the variation of activity from case toHYPERCITRICEMIA IN HUMAN CANCER 387
TABLEIX.-Enzyme, Activity of Venous Blood and Citrate Concentration
Copper
resistant
acid
phosphatase
(.tmole phenol/
100 MI.)
Under 24 Vmole/
100 ml.
38-8±4-2 S.E.
(27)
40-1±6- 9
(13)
46-8±4- 9
(10)
33-3±5- 6
(19)
32-8±4- 6
(10)
Alkaline
phosphatase
(Bodansky
Sex units)
. M. 'LTnder 5
Phosphohexose
isomerase
(Bodansky
units)
Under 40
42- 6
(22)
Glutamic Fasting
oxalacetic citrate
transaminase concentration
(units) (lig./ml.)
Under 20 27-2±1- 3
units (27)
38-31L I
- 8
(44)
17- 5 45.2±3.8 S.E.-
(8) (29)
Group
Normal .
F.
Metastatic carcinoma
of breast
No therapy
Same, prednisone
therapy 6 months or
less
Same, prednisone for
over 6 months
Other metastatic car- M.
cinoma
No therapy
Other metastic car- F.
cinoma
No therapy
5-954-1-13 S.E.
(19)
7- 3
(3)
14- 6
(5)
5-8+1- 7
(12)
8-2+3- 2
(6)
69-2+ 18-6 15 33-6+2-9
(10) (4) (13)
63-3+52
(9)
41- 6+5- 6
(14)
35-8 44-3±5-9
(4) (12)
12 43
-9±3
- 8
(3) (25)
53-4± 14-5 12-7 39-9±5-0
(10) (3) (15)
Numbers in parentheses indicate number ofpatients tested, upon which mean ± S.E. is based.
case was great. In this latter group, enzymatic abnormalities also appeared
to vary independently of citrate concentration in many inclividual cases.
10. Reduction of elevated citrate concentration in mammary cancer by anti-estrogenic
therapy withprednisone.
During these studies, hormonaltherapyconsisting ofoophorectomy inpatients
under 64 years of age, combined with pituitary-adrenocortical suppression
utilizing prednisone 20-30 mg. daily was given to many of the new advanced
breast cancer cases (Lemon, 1959). Serial observations of the immediate effects
of prednisone administration upon citrate dynamics were made in 7 healthy
volunteers and in 10 cancer patients. An inconsistent change in fasting venous
citrate was noted in healthy volunteers receiving prednisone, while the cancer
patients with hypercitricemia (including one with bronchogenic carcinoma) in
nearly all cases had asignificant (p
= < -01) reduction of citrate concentration to
normal female or even normal male values during the first 6 months of treatment
(Table IX). This fall in venous citric acid concentration was accompanied
by a mean 28 per cent reduction in 18 estimations ofthe clearance rate ofinjected
citric acid in chiefly female cancer patients, whose gonads had been ablated
(Tables 111, X). The less regular reduction of citrate clearance rate was noted in
healthy volunteers, whose intact gonads possibly partially nullified the anti-
estrogenic effects of prednisone therapy, and whose citrate concentrations were
initially within the normal range. These observations appear consistent with a
cortisone inhibition of citrate diffusion into blood in cancer patients, leading
to a reduction of blood citrate concentration in spite of reduced citrate uptake by
tissues.
It was striking to note the recurrently elevated blood citrate values when
patients relapsed while on adrenal corticoid therapy (Table XI).388 LEMON, MUELLER. LOONEY. CHASEN AND KELMAN
TABLE X.-Effect ofPrednisone Therapy on Citrate Clearance (C) in
Volunteers and Cancer Patients
Cancer
patients
(Male)
F. C-
. (Female)
E. W-
I. G-
H. A-
9 9
P. I-
ill,
513,
B. L-
B. T-
L. M-
A. M-
M. C-
m. L-
99
.
II patients
Per cent
change
from
Duration pre-therapy
therapy observation
Per cent
change
from
Duration pre-therapy
therapy observation Healthy
volunteers
(Male)
J. L
J. s
B. I
R. N
Origin
Lung
Breast
Endometrium
Breast
9 9
91,
p 91
9 p
. 91
3 days
91,
319,
519
8 days
I day
27 days
2 days
6 weeks
2i months
6 days
2 months
5 months
6 months
9 days
I1 days
9 months
I year
12 days
6 months
9 days
2 weeks
-70
+31
-63
-13
+22
-41
-61
-43
+18
+31
-46
-67
+ 3
24
-14
-90
-60
-22
Mean
= -28%
(18 tests)
+55
+75
-12
-37
-11
-36
-62
(Female)
L. K
R. D
V. D
(Dosage
=30 mg./day)
7 patients Mean
= -4%
(7 tests)
TABLIF, XI.-Recurrence of Hypercitricemia During Clinical Relap8e of Advanced
Mammary Cancer Treated by Predni8one
Initial
venous
citrate
([Lg./
MI.)
64- 8
Venous citrate
during terminal
relapse (therapy
continued)
([Lg./M,.)
62- 3
Mean, range of
venous citrate
duration theraputic
remission
30-5 (23-1-37-2)
Tiirne
before
death
1 month
2 weeks
I month
1 month
Duration
therapy
6 months
Patient
H. A-
B. L-
H. C-
K. L-
L. M-
L. T-
P. I-
F. C-
M. L-
Metastases
Bone, liver
later
Bone, lung
Brain, lung
Lung,
mediastinum
Skin, bone,
liver later
Bone, lung
Bone
64- 8 49-4 (47-4-51-4)
loo+ 20- 2 (18-5-21-9)
69- 5 50.0
I month 103
-0
2 months 100+
2 months 30
-4
50
79':0
57- 2
89- 5
loo+
34-8 (27-4-41-9)*
34-1 (30- 2-38-0)
30- 1 (18- 8-40-3)
29-4 (19-4-39- 1)
34- 5 (22-2-49-7)
39-4 (21-6-60-8)*
31-5 (16-3-39-1)
35- 0
I year
18 months
7 months
18 months
2 years
76- 1*
116- 6
23- 9
75- 9 (62-95-5)
47- 9 (26-9-64)
79-2 (66-106)*
39- 1
2 months
I week
I month
3 months
7 months
(Livmg
Mean ofpatients means: 75 65-9
* Temporary relapse.389 HYPERCITRICEMIA IN HUMAN CANCER
DISCT-TSSION
Hypercitricemia in various types of cancer has not been frequently noted by
several previous observers (Schersten, 1931 ; Rottino, Hoffman and Brondolo,
1952) with asingle undocumentedexception(Kyle andCanary, 1957). RI.-Iview of
the case material utilized in several of these papers indicates that only a small
number ofpatients were studied, ofwhom many hadalready received anti-cancer
therapy. Furthermore, it is not clear whether fasting bloods were always
utilized for analyses, which will usually yield the peak venous citrate concentra-
tions. Relatively few case reports are included of breast, prostate and lung
carcinomata which comprise the majority of our patients with hypercitricemia.
Simultaneous pre-selected control groups were not used in some previous studies,
retrospective controls being used. These differences appear to explain most of
the discrepancies between our observations, and previous reports.
In spite of inflammatory disease involving bone and joints in rheumatoid
arthritis and metabolic disorders, such as post-menopause osteoporosis, serum
citrate wasnormalin all non-cancer cases. Atrophic bonechanges werefrequently
widespread as shown by X-ray at the time of our sampling. This suggests that
citrate measurement can be a usefuladjunct in differentialdiagnosis ofthebenign
or malignant nature of some osseous lesions, in which demineralization is a
prominent feature.
From our observations hypercitricemia appears to be a relatively common
disorder usuaRy independent of hypercalcemia in patients with advancing neo-
plastic disease invading liver, lung or bone among other tissues. Hypercitri-
cemiaduring active cancergrowth is ofparticular interest in that it mayrepresent
adysfunction of the Krebs cycle through excessive citrate production or deficient
citrate utilization via condensation to acetoacetate, either in cancer or normal
tissues or both. Destruction of the activity ofCoenzyme 11 (TPN) might result
in such a disturbance. In adclition citrate equilibrium in osseous tissues may be
disturbed, as seen inhyperparathyroidism orPaget's disease withhypercitricemia
secondary to osteolysis (Kissin and Kreeger, 1954; Chang and Freeman, 1950b).
In this latter case, a negative calcium balance and hypercalcemia might be
expected to accompany hypercitricemia, as we have observed in one case of
functioning parathyroid carcinoma and in occasional mammary cancer patients.
Intensive osseous destruction, although present roentgenologically in many of
the hypercitricemia breast cancer patients, was not severe enough to induce
hypercalcemia in most of these patients and may be coincidental, rather than
contributory.
Gomori andGulyas (1944) were the first to observe thatparenteral administra-
tion ofsodium citrate in dogs leads to marked hypercalcuria with
i 'mal altera-
tion in serum calcium concentration. Their work has been confirmed (Chang and
Freeman, 1950a), indicating that in the absence of hyperparathyroidism and its
attendant metabohc disturbance hypercitricemia may produce a ten to twenty
fold augmentation of calcium excretion without raising total serum calcium
concentration above 12 mg. per cent. This may be the result of a marked increase
in the ultra-filterable fraction ofplasma calcium which is citratebound, or because
of diminished tubular reabsorption of the calcium citrate complex. These
observations bowever help to explain the rare coexistance ofhypercitricemia and
hypercalcemia in our cancerpopulation.390 LEMON, MUELLER, LOONEY, CHASEN AND KELMAN
Hormoiial factors such as insulin (Pincus, Natelson and Lu-uovov. 1.949),
epinephrine (Pincus, Na-telson and Lugovoy, 1951) and adrenocortical hormones
(Piiicus, Natelson and Lugovoy, 1951 ; Agrell, Lindell and Westling, 1955) also
have been shown to alter venous citrate concentration. None of our hypercitri-
cemic cancer patients was diabetic or receiving insulin, nor did we encounter any
pheochromocytomas in our series of cases. Although adrenocortical insufficiency
results in hypercitricemia in man (Martenesson, 1949), none of our patients was
suffering from acute adrenocortical insufficiency at the time of our studies, and
only oiie patient with leiomyosarcoma metastatic to the adrenal glands was
receiving adrenal steroid therapy, as a result of a previous Addisonian crisis. At
the time of our study this patient was in electrolyte balance. Although the
kidneys serve as a major site of citrate uptake from blood, significant impairment
of renal function was not present in our hypercitricemia patients. Hepatic
insufficiency was also absent in most hypercitricemia patients, including those
with hepatic metastases. No evidence was obtained that hypercitricemia was
related to any reduction of citrate uptake fiom blood (Table 111).
The striking reduction of venous citrate concentrations to normal inpreviously
hypercitricemia breast cancer patients receiving cortisone or prednisone, occurred
in spite of a 28 per cent reduction in clearance rate for injected citrate. This
depression of citrate uptake from blood by adrenal steroid therapy in all likeli-
hood is closely related to the reduction of acetate utilization which has also been
reported. Hennes and Shreeve administered doses of prednisone identical to
those we have utilized, to patients receiving 14C-labelled acetate, and noted an
initial reduction of 20-30 per cent in rate of radiocarbon excretion compared to
control observations (Hennes and Shreeve, 1959). Over a 24 hour period a 10-15
per cent reduction of cumulative radioactivity excretion was demonstrated.
Henneman and Bunker have reported elevated venous lactate and pyruvate
concentrations following adrenal steroid therapy and in Cushings' svndrome
(Henneman and Bunker, 1957), suggesting a decrease in pyruvate oxidation under
these circumstances. Impairment of glucose tolerance has long been recognized
as one of the most dependable laboratorv manifestations of adrenal cortical
hyperfui-iction.
The control ofhypercitricemia by adrenal steroid therapy must be accounted
for by reduced citrate diffusion into blood from some tissue source. Not only
must this diffusion rate be very high prior to therapy to induce hypercitricemia,
in view of the 20-25 g./day capacity of the body to utilize citrate, but steroid
induced inhibition of diffusion from this tissue source must far exceed the net
overall reduction in uptake of citrate caused by prednisone therapy. Our
observations indicate that a major source of citrate enrichment of blood exists in
the sinusoids of bone marrow, where at all times citrate concentration exceeds
that of mixed Feripheral arterial or venous blood. Adrenal steroid therapy
apFears to have a more marked and consistent effect reducing venous citrate of
breast cancer patients than that of healthy volunteers. However, differences
in the duration and intensity oftherapy or in the degree of sex hormone inhibition
so induced, may account for this variation in response. The greater prevalence of hypercitricemia in advanced breast, prostate and lung carcinoma patients in
whom osseous metastases are so common (Table 111) and the infrequency of
occurrence in benign tumors or localized breast cancer suggest that hypercitri- cemia is potentiated by widespread neoplastic invasion of bone marrow. TheHYPERCITRICEMIA IN HUMAN CANCER 391
simultaiieous elevation of venous acid phosphatase in hypercitricemic patielits
also supports bone marrow invasion as the chief source for excessive diffusioii of
citrate into blood, since this enzyme is elevated in vei-ious blood in 75 per c--iit
of patieiits with osseous metastases of breast or prostate careii-ioma prior to
tlierapy (Reyiiolds, Lemon and Byrnes, 1956). We have also found that marrow
siiiiisoid blood is far higher in acid phosphatase activity, than peripheral arterial
or venous blood (Reynolds, Lemon, Kaplan, Idelson, Mueller and Derow, 1959).
Likewise, abnormal venous phosphohexose isomerase activity is often preseiit in
iiiami-iiary carcinoma with osseous invasion (Bodansky, 1954a), aiid elevated
alkaline phosphatase activity is well knowi-i to result from osseoiis or hepatic
invasion by tumour.
Since the early reports of Dickens and others coi-iceriiiiig the presei-ice of
citrate in the organic matrix of vertebrate bone (Dickens, 1941 ; Thunberg, 1953),
which contains 95 per ceiit of total body citrate, a great deal of work has beeil
carried out showing a close relatioi-iship between calcium and citrate metabolism
in response to various stimuli, and a current hypothesis ofboiie formatioii includes
precipitatioii of calcium citrate on the superficial lamellae of bDiie trabe-l-Iulae
(Neumann and Neumaiin, 1958). Enzymes necessary for local productioli of
citrate haNTe been described in osteoid tissue (Dixon and Perkins, 1952). Olie
observed case ofosteogeiiesis imperfecta, in a 5 year old boy, had a venous citrate
of 8.9-5 /ig./ml. prior to therapy, falling to a normal value after t3stosterone_
therapy had ii-iduced some calcification and clinical improvement. The move-
ineiit ofcalcium and citrate in and out ofbone under the influence ofparathormoiie
or X'itamin 1) therapy is generally in the same direction (Carlsoi-i aiid Hollunger,
1954 ; Elliott and Freeman, 1956), and a similar treiid is apparent in our data.
IA'itli the exception ofprostatic carcinoma which rarely induces hypercaleemia or
hypercalcuria, caiicer frequently resulting in hypercitricemia such as lung o---
breast are also prone to develop hypercaleemia. When the latter dl-lvelops,
liypercitricemia usually co-exists. The
" Idiopathic
" hyperealcemia reported in
advanced lung, breast, ovarian or renal cancer cases in the absei-ice of d--tectable
osseous metastases may be possibly associated with hypercitricemia, if the latter
abiiormality were to be looked for (Plimpton and Gellhorn, 1956). A calciuni-
biiiding substance has been postulated in those cases in whom an elevated seran-i
alkaline phosphatase suggested bone disease.
Normal prostatic and mammary epithelium secrete extremely high conceiitra-
tioiis of citric acid into their respective secretions as a result of specific sex
hormonal stimulation (Mann, 1954 ; Lenner, 1934) and this function possibly is
preserved in some endocrine dependent cancers. Talalay and Williams-Ashmaii
have postulated that estrogenic cellular stimulation is mediated via effects upoii
the balance of pyridine nucleotide dependent transdehydrogenase systems.
involved in the function of the Krebs cycle (Talalay and Williams-Ashman, 1958),
which would therefore govern the production and/or utilization of citr-ate by
hormone sensitive tissues.
Our one negative observation of citrate diffusion from breast cancer occurred
in a patient with primary disease lacking demonstrable lymphatic or osseous
metastases and whose venous blood levels were normal. If tumor cells in bone
marrow served as a major source for thehigh citrate concentrations we have noted,
osteolytic bone destruction might be explained by the reversal of the normal
processes of calcification, through creation of excessive amounts of free citrate in
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the diseased sinusoids to compete with phosphate for the calcium hydroxyapatite
(Neumann and Neumann, 1958). Neoplastic invasion of soft tissues may also be
facilitated by citrate induced solvation ofprocollagen (Jackson, 1957).
Numerous observations attest to the striking ability of cortisone and pred-
nisone therapy to control hyperealcemia in cancer, and to induce recalcification
of osseous metastases in breast cancer, coincidental with reduction of circulating
citrate concentration to normal (Lemon, 1956, 1957, 1959 ; Nissen-Meyer, 1957).
Adrenal corticoids have been shown to antagonize the action of estrogens upon
hormone-dependent target tissues such as endometrium, nullifying both water-
inhibition and growth (Szego and Roberts, 1953 ; Huggins and Jenson, 1955 ;
Velardo, Hisaw and Bever, 1956) as well as exerting a depressing influence upon
the growth of a number of different types of transplantable and spontaneous
cancers (Pearson, Li, MacLean, Lipsett, and West, 1955 ; Rusch, 1956). As a
working hypothesis it may be postulated that the normalization of venous citrate
and subsequent recalcification of some osseous metastases may also represent the
result of direct inhibitory effects exerted upon osseous mammary carcinoma
metastases as well as indirect effectssecondary todepressed sex hormone secretion.
Our data is insufficient as yet concerning the influence of steroid therapy upon
hypercitricemia in other types of metastatic cancer to draw further inferences.
Although clinically obvious metastases were noted in hepatic or pulmonary or
other areas without radiologically detectable bone involvement in 71 per cent of
,our hypercitricemia cases with metastatic cancer (Table VII) the prevalence of
-circulating tumour emboli in over 50 per cent of patients with malignant neo-
plasms insures that the sinusoids of bone marrow become the repository of
active or inactive metastases, sooner or later in most forms of advanced cancer
(Fisher and Turnbull, 1955 ; Moore, Sandberg and Schubarg, 1957 ; Engell,
1955).
Finally, hypercitricemia to the levels which we have observed must produce
some major disturbances of membrane permeability, resulting from alteration of
the mono-valent to di-valent cation ratio through calcium binding by elevated
citrate. Normally female venous blood coiitains about 0-6 m-equiv./l. of citrate
(38 pg./ml.) capable of binding a similar amount of ionized calcium (Hastings,
MacLean, Eichelberger, Hall and Da Costa, 1934). About 65 per cent of serum
calcium is normally ultra-filterable or 3-24 m-equiv./l. (Neumann and Neumann,
1958). Bicarbonate, phosphate and citrate are the principal anions available to
bind diffusible calcium. Under normal circumstances, ionized calcium averages
.about 2-66 m-equiv./I., so that citrate bound serum calcium constitutes a labile
fraction amounting to nearly one-sixth of total diffusible calcium. If citrate
concentration rises to the values herein reported, then 1-0-1-8 m-equiv./l. or more
of serum calcium ion might be complexed with citrate, assuming no shift of the
latter from protein, leaving only an estimated 1-2 m-equiv./l. of ionized calcium
for control of membrane permeability. Hastings and co-workers clearly showed
that calcium citrate was metabolically inert in so far as the frog heart was con-
cerned, up to values as high as 20 m-mole/l. (Hastings, MacLean, Eichelberger,
Hall and Da Costa, 1934), and hence cannot function in the control of membrane
permeability.
Contrary to some earlier reports (Allen, Clark, Thornton and Adams, 1944)
hypercitricemia has been observed as a hazardous complication of exchange
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massive blood replacement therapy in adults with hepatic cirrhosis and bleeding
varices, major vascular surgery and major operations in the portal area (Bunker,
Stetson, Coe, Grillo and Murphy, 1955). Bunker and co-workers observed that
the immediate rise in serum citrate after infusion ofvarying amounts of citrated
blood varied with the rate of administration and total amount of blood infused.
Somewhat higher arterial blood levels were observed in patients with hepatic
disease, than in other pre-operative patients under pre-medication. Values were
noted as high as 300-400 jig./ml. in their series (+ 5-0-6-5 m-equiv./l.). Depres-
sion of ionic calcium concentration calculated on the basis of total calcium,
total protein and citrate concentration (Hastings, MacLean, Eichelberger, Hall
and Da Costa, 1934) to values as low as 1-10-I
-40 m-equiv./1. was associated with
hypotension or shock in the majority of cases, a few of whom responded to
intravenous calcium ion therapy. Only rarely did their patients show tetanic
manifestations which we have not observed as yet, either. With calculated
ionic calcium above 1-50 m-equiv./I., no hypotensive phenomena were observed.
Less deleterious subjective effects may result from smaller elevations of serum
citrate such as we have noted, which consisted primarily of anorexia and nausea,
and emphasize that hypercitricemia may contribute to malaise of the cancerous
patient. Reduction of blood citrate levels to normal by prednisone therapy,
and the simultaneousstrikingsubjectiveimprovement ofmanypatients, including
their strength and appetite, may be related to a restoration of a more normal
ionic cellular environment.
In most of the adult surgical patients in whom massive replacement of blood
is necessary, extreme activation of the pituitary-adrenocortical system by the
underlying catastrophic disease probably contributed to hypercitricemia, by
impairing the metabolism of exogenous citrate, such as we have observed occurs
after adrenal cortical steroid therapy.
Cookson and co-workers have suggested that hypothermia which has been
utilized in vascular surgery may compound the hazard by further reduction of
ability to utilize large amounts of administered citrate (Cookson, Costas-Durieux
and Bailey, 1954). Anoxia per se may also induce hypercitricemia (Hallman and
Forsander, 1952).
Bunker and co-workers obtained fairly satisfactory agreement between the
observed increment in arterial citrate concentration after infusion (average in
11 patients=13-7 mg./100 c.c.) and the increment predicted on the basis of
equilibration in extracellular fluid within 6-16 minutes (average=11.2 mg./100
c.c.) If the latter figure is corrected for the mean rate of fall we-have noted in
serum citrate concentration after termination of infusion, approximately 1 #g.1
ml./minute in both sexes in the period 5-30 minutes after injection, the expected
citrate concentration would be 12-5 mg./100 c.c. from their data, on the assump-
tion that the clearance process begins immediately with initial elevation of serum
citrate. It is likely that the amount ofprotein bound calcium was overestimated
from the total protein concentrations observed in many of the patients with
hepatic cirrhosis in the series reported by Bunker et al. (1955) in whom a
considerable increase in gamma globulin fraction could be expected, which has
been found to have only slight calciumbinding capacity (Carr, 1955). Therefore,
their estimates of residual ionic calcium may be somewhat on the low side. Not
all recent.investigators have found hypercitricemia after massive transfusion, no
doubt due partly to the very rapid utilization of citrate which all have noted,
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even with advanced liver disease (Howland, Bellville, Zucker, Boyan and Cliffton,
1957).
SUMMARY
Citric acid concentration has been measured using the pentobromoacetone
procedure in blood from bone marrow, arterial and venous sites, in 358 healthy
volunteers, arthritics and patients with various types of cancer in all stages. The
clearance of exogenous citrate from blood has been estimated in a representative
fraction ofeach group ofpatients and approximates 0 9 g. per hour. Women have
been found to have consistently higher fasting venous serum citric acid than men,
with a slightly lower citrate clearance rate. Bone marrow blood consistently
shows the highest concentration of citrate, followed by arterial and finally venous
blood. Venous citric acid concentrations greater than twice the S.D. from the
mean for each sex (" hypercitricemia ") occurred in 4-2 per cent of healthy
volunteers, in 4-6 per cent of all patients with benign diseases, in 11 1 per cent of
patients with pre-malignant tumors, and in 23-6 per cent of patients with lancer.
Anorexia and weakness were generally noted in the latter group. Hypercalcemia
exceeding 12 mg. per cent (6 m-equiv./l.) was noted in only 3 patients in the
entire series, but abnormal acid phosphatase and lactic dehydrogenase activity
usually accompanied hypercitricemia. Advanced carcinomas of the breast,
prostate, and lung were most commonly associated with hypercitricemia, probably
as a result of osseous metastases. Prednisone therapy in advanced mammary
carcinoma usually reduced elevated blood citric acid to normal simultaneously
reducing by 28 per cent the utilization of administered citrate, indicating the
probable suppression of tumor growth in osseous and perhaps in other metastatic
sites.
These studies have been supported by a research grant from the National
Cancer Institute, by the Rebecca Rice Memorial Grant of the American Cancer
Society to Boston University, by a grant from the Quincy United Fund, of
Quincy, Massachusetts, and a student research fellowship from the Massachusetts
Arthritis and Rheumatism Foundation.
REFERENCES
AGRELL, I., LINDELL, S. E. AND WESTLING, H.-(1955) Acta physiol. scand., 34, 135.
ALLEN, J. G., CLARK, D. E., THORNTON, T. F. AND ADAMS, W. E.-(1944) Surgery, 15,
824.
BODANSKY, A.-(1932) J. biol. Chem., 99, 197
BODANSKY, O.-(1954a) Cancer, 7, 1191.-(1954b) Ibid., 7, 1200.
BUNKER, J. P., STETSON, J. B., COE, R. C., GRILLO, H. C. AND MURPHY, H. D.-(1955)
J. Amer. med. Ass., 157, 1361.
CARLSON, A. AND HOLLUNGER, G.-(1954) Acta physiol. scand., 31, 317.
CARR, C. W.-(1955) in 'Electrochemistry in Biology and Medicine', Shedlovsky, T.
(ed.). Chapter 14. New York (John Wiley and Sons).
CHANG, T. S. AND FREEMAN, S.-(1950a) Amer. J. Physiol., 160, 330.-(1950b) Ibid.,
160, 341.
CLARKE, E. P. AND COLLIP, J. B.-(1925) J. biol. Chem., 63, 461.
COOKSON, B. A., COSTAS-DURIEUX, J. AND BAILEY, C. P.-(1954) Ann. Surg., 139, 430.
CORI, C. F. AND CORI, G. T.-(1925) J. biol. Chem., 65, 397.HYPERCITRICEMIA IN HUMAN CANCER 395
DICKENS, F.-(1941) Biochem. J., 35, 1101.
DIETRICH, L. A. AND SHAPIRO, D. M.-(1956) Cancer Res., 16, 585.
DIxoN, T. F. AND PERKINS, H. R.-(1952) Biochem. J., 52, 260.
ELLIOTT, J. R. AND FREEMAN, S.-(1956) Endocrinology, 59, 200.
ENGELL, H. C.-(1955) Acta chir. scand., Supp. 201, 1.
ETTINGER, R. H., GOLDBAUM, L. R., SMITH, L. H.-(1952) J. biol. Chem., 199, 531.
FISHER, E. R. AND TURNBULL, R. B.-(1955) Surg. Gynec. Obstet., 100, 102.
FISKE, C. H. AND SUBBAROW, Y.-(1925) J. biol. Chem., 66, 375.
FRANCO.-(1957) 'Sigmo-Franco Procedure', Sigma Chem. Co. Tech. Bulletin, No. 505.
GoMORI, G. AND GULYAS, E.- (1944) Proc. Soc. exp. Biol. N.Y., 56, 226.
HASTINGS, A. B., MACLEAN, F. C., EICHELBERGER, L., HALL, J. L. AND DA COSTA, E.
-(1934) J. biol. Chem., 107, 351.
HALLMAN, N. AND FORSANDER, O.-(1952) Ann. Med. exp. Fenn., 30, 287.
HENNEMAN, D. H. AND BUNKER, J. P.-(1957) Amer. J. Med., 23, 34.
HENNES, A. R. AND SHREEVE, W. W.-(1959) Proc. Soc. exp. Biol. N.Y., 100, 246.
HERNDON, R. F. AND FREEMAN, S.-(1958) Amer. J. Physiol., 192, 369.
HILL, B. R. AND LEVI, C.-(1954) Cancer Res., 14, 513.
HOWLAND, W. S., BELLVILLE, J. W., ZUCKER, M. B., BOYAN, P. AND CLIFFTON, E.-
(1957) Surg. GAynec. Obstet., 105, 529.
HUGGINS, C. AND JENSON, E. V.-(1955) J. exp. Med., 102, 347.
JACKSON, D. S.-(1957) 'Connective Tissue. A Symposium'. Tunbridge et al. (ed.).
Oxford (Blackwell Scientific Publications), p. 62.
KISSIN, B. AND KREEGER, N.-(1954) Amer. J. med. Sci., 228, 301.
KYLE, L. H. AND CANARY, J. J.-(1957) J. Lab. clin. Med., 49, 590.
LEMON, H. M.-(1956) Clin. Congr. Amer. Coll. Surg., 6, 415.-(J]957) Annals intern.
Med., 46, 457.-(1959) Cancer, 12, 93.
Idem, DAVISON, M. D. AND ASIMov, I.-(1954) Ibid., 7, 92.
Idem, MUELLER, J. H,, LOONEY, J. M. CHASEN, W. H. AND KELMAN, M.-(1959) Boston
med. quart., 10, 1.
LENNER, A.-(1934) Acta obstet. gynec. scand., Supp. 1; 14, 1.
MANN, T.-(1954) 'The Biochemistry of Semen'. London (Methuen and Co., Ltd.),
p. 16.
MARKS, P. A. AND BISHOP, J. S.-(1957) J. clin. Invest., 36, 254.
MARTENSSON, J.-(1949) Acta med. scand., 134, 61.
MILLER, H. AND CARRUTHERS, C.-(1950) Cancer Res., 10, 636.
MOORE, G. E., SANDBERG, A. AND SCHUBARG, J. R.-(1957) Ann. Surg., 146, 580.
NEUMANN, W. F. AND NEUMANN, M. W.-(1958) 'The Chemical Dynamics of Bone
Mineral '. (Univ. of Chicago Press), p. 209.
NISSEN-MEYER, R.-(1957) Acta endocr., Supp. 31, p. 314.
PEARSON, 0. H., LI, M. C., MAcLEAN, J. P., LIPSETT, M. B. AND WEST, C. D.-(1955)
Ann. N.Y. Acad. Sci., 61, 393.
PINcus, J. B., NATELSON, S. AND LUGOVOY, I. K.-(1949) J. clin. Invest., 28, 741.-
(1951) Proc. Soc. exp. Biol. N.Y., 78, 452.
PLIMPTON, C. H. AND GELLHORN, A.-(1956) Amer. J. Med., 21, 750.
POTTER, V. R. AND BUSCH, H.-(1950) Cancer Res., 10, 353.
RECHENBERGER, J. AND BENNDORF, S.-(1956) Z. Altersforsch., 10, 49.
REYNOLDS, M. D., LEMON, H. M. AND BYRNES, W. W.-(1956) Cancer Res., 16, 943.
Idem, LEMON, H. M., KAPLAN, G. A., IDELSON, B. A., MUELLER, J. AND DEROW, M. A.
-(1959) Proc. Amer. Ass. Cancer Res., 3, 56.
ROTTINO, A., HOFFMAN, G. T. AND BRONDOLO, B.-(1952) Proc. Soc. exp. Biol. N.Y.,
80, 339.
RUSCH, H. P.-(1956) Cancer Res., 16, Supp. 4, p. 183.
SAFFRON, M. AND DENDSTADT, 0. F.-(1948) J. biol. Chem., 175, 849.
SCHERSTEN, B.-(1931) Skand. Arch, Physiol., 63, 97.396 LEMON, MUELLER, LOONEY, CHASEN AND KELMAN
SCHWARTZ, M. K., GREENBERG, E. AND BODANSKY, O.-(1959) Proc. Amer. A88. Cancer
Res., 3, 61.
SIBLEY, J. A., FLEISCHER, G. A., HIGGINS, G. M.-(1955) Cancer Res., 15, 306.
STARK, J. B., GOODBAR, A. E. AND OWENS, H. S.-(1951) Analyt. Chem., 22, 413.
SZEGO, C. M. AND ROBERTS, S.-(1953) Recent Progr. Horm. Res., 8, 419.
TALALAY, P. AND WILLIAMS-ASHMAN, H. G.-(1958) Proc. nat. Acad. Sci., Wash.,
44, 15.
THUNBERG, T.-(1953) Physiol. Rev., 33, 1.
VELARDO, J. T., HISAW, F. L., BEVER, A. T.-(1956) Endocrinology, 59, 165.
WEXLER, I. B., PINCUS, J. B., NATELSON, S. AND LUGOVOY, I. K.-(1949) J. cdin.
Invest., 28, 474.
WOLFSON, S. K., SPENCER, J. A., STERKEL, R. L. AND WILLIAM-ASHMAN, H. G.-(1958)
Ann. N.Y. Acad. Sci., 75, 260.
YARBO, C. L.-(1956) J. Urol., 75, 216.